PM Society Market Access Interest Group
Market access is central to the success of the healthcare industry and to patient outcomes. The term
means something different to each of these stakeholder groups and equally to individual companies,
health providers or patient organisations, according to their size and needs.
Principally market access involves preparing a positive environment which supports uptake of your product
and demonstrating the ‘value’ of your product to the range of customers who influence uptake.
Strategically, market access is about packaging data in the right way, for the right customer at the
The PM Society Market Access Interest Group addresses the growing need for multiple stakeholders to understand their role in ‘market access’. Discussions are likely to be as diverse as the pharma/life sciences industries-patient dialogue, evidence requirements in the context of payer needs, the role of NHS liaison and the move from risk-sharing to value-based pricing. The Market Access group will also look to define, for the first time, the pharma and life sciences industries’ priority concerns relating to market access and, in time, to find practical solutions for overcoming barriers and establishing best practice.
We meet regularly to discuss common issues and focuses on:
- Learning and education
- Celebrating best practice
- Providing an opportunity to exchange ideas and network
Membership of the group is open to anyone with an interest in market access in its broadest sense, but
the Society is particularly keen to hear from industry representatives.
Please email Helen or call
01403 264898 if you are interested in finding out more or to join the group.
New Scotland ultra-orphan access pathway
On June 18th 2018 the Scottish Health Minister, Shona Robison, announced a new access pathway for
‘ultra-orphan medicines’ in Scotland – medicines that can treat very rare conditions affecting fewer than 1 in 50,000 people.
This new development follows on from Dr Brian Montgomery’s Review of Access to New Medicines, published in December 2016,
which noted a low approval rate for medicines for very rare conditions.
To resolve this, the report recommended the development
of an alternative assessment pathway for ultra-orphan medicines. If a treatment meets the new definition of an ultra-orphan medicine
and the Scottish Medicines Consortium (SMC) consider it clinically effective, then it will be made available via NHS Scotland for
at least three years while information on its effectiveness is gathered.
The new pathway is scheduled to commence on October 1st 2018.